Technology Name | Briefcase | Lead Researcher |
---|---|---|
Category
LifeSciences and BioTechnology
Keywords
Natural compounds, Synthetic compounds, Neurodegenerative disorders
Current development stage
For Pharmaceutical development: TRL4 - POC & Safety of candidate drug formulation is ... More | Tsvelikhovsky Dmitry | |
Background
Oxazine, Azaspirone, Quinolines, Quinolinone, and Quinolinol structures are frequently observed as scaffold segments in various biochemical compounds. These architectures have been identified as building blocks of a numerous ... More | Tsvelikhovsky Dmitry | |
Background
Methylene lactone structures are frequently observed as scaffold segments of various biochemical compounds.
These architectures have been identified as building blocks of numerous terpenoids, as well as other families of diverse ... More | Tsvelikhovsky Dmitry | |
Background
As for today, an oral treatment to metastasis therapy is still an unmet challenge. We discovered a new approach to treat metastatic disease in that was verified in several preclinical models.
Our Innovation
A new approach to treat ... More | Reich Reuven | |
Categories
Small molecules, anti-inflammatory treatment
Development Stage
In-vivo proof of concept
Patent Status
Patent application filed
Market
Inflammation indications: acute pancreatitis, acute live damage, fatty liver damage, ... More | Weinstock-Rosin Marta | |
Background
A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein, such as dystrophin in Duchenne muscular dystrophy. Nonsense mutations caused by premature stop codon, are treated ... More | Karni Rotem | |
Additional information will be provided upon request
More | Domb Abraham | |
Additional information will be provided upon request
More | Domb Abraham | |
Background
Toll-like receptors (TLRs) have been implicated in several autoimmune and inflammatory diseases, including cancer, diabetes, cardiovascular disease, atherosclerosis, Alzheimer’s disease, and chronic neuropathic pain.
Currently, ... More | Goldblum Amiram | |
Background
Age Related Macular Degeneration (AMD) is the leading cause of blindness in elderlies in the western world and an increasingly growing problem. The global AMD and diabetic retinopathy treatment market is overwhelmingly dominated by ... More | Benny Ofra | |
Category
LifeSciences and BioTechnology
Keywords
Natural compounds, Synthetic compounds, Neurodegenerative disorders
Current development stage
For Pharmaceutical development: TRL4 - POC & Safety of candidate drug formulation is ... More | Tsvelikhovsky Dmitry | |
Background
Non-alcoholic fatty liver disease (NAFLD) and associated diseases Non-alcoholic steatohepatitis (NASH), Cirrhosis, and Hepatocellular carcinoma (HCC) cost the US economy an estimated at $103 billion per year. Lipotoxicity is a major ... More | Tirosh Oren | |
Background
Obesity is the leading cause of death in America, and is associated with an increase in chronic diseases like, cardiovascular diseases, hypertension, and metabolic disease involving the liver as well as type 2 diabetes. A recent study ... More | Monsonego-Ornan Efrat | |
Background
Cancer cells lose their epigenetic checks and balances followed by unscheduled shut-off of tumor-suppressor genes and switch-on of genes that promote cell proliferation.
1st generation of anti-cancer epigenetic drugs are ... More | Ben-Sasson Shmuel | |
Categories
Superactive High Afinity Leptin antagonist, mutein, multiple sclerosis, inflammatory bowel syndrome, rheumatoid arthritis, fibrosis, cardiovascular disease, CKD Cachexia, Osteoarthritis
Development Stage
(1) In vivo tests in ... More | Gertler Arieh | |
Our Innovation:
Drug-eluting stents (DES) are widely used in intravascular intervention.
The current technology is based on crystallization of drug onto stent surface (with no- polymer) Coating process is resulting in high yield coatings that ... More | Domb Abraham | |
Additional information will be provided upon request
More | Shoseyov Oded | |
Category
LifeSciences and BioTechnology
Keywords
congestive heart failure, atrial fibrillation, cardiac steroids
Current development stage
For Pharmaceutical development: TRL4 - PoC&Safety of candidate device or system is ... More | Lichtstein David |